News. Analysis. Insight.™ - 100 Years of Journalistic Excellence

Vaxgen is a biopharmaceutical company focused on the development, manufacture and commercialization of biologic products for the prevention and treatment of human infectious disease. Co. is developing vaccines against inhalation anthrax and smallpox for the purpose of biodefense. In collaboration with the Chemo-Sero-Therapeutic Research Institute of Japan ("Kaketsuken"), Co. is also developing, for use in the United States and internationally, LC16m8, an attenuated smallpox vaccine candidate. Co. is developing rPA102, a recombinant Protective Antigen anthrax vaccine candidate, with the assistance of funding from its NIAID Contracts.

Industry	Health
Sector	Pharmaceuticals
# of Employees	216
Shares Outstanding	33.1M
Market Cap	16.3M
Enterprise Value	-

52-Week High	$1.00
52-Week Low	$0.33
P/E Ratio	-3.51
EPS	-$0.14/shr
Dividend	-
Yield	-

Dr. Randall L-W. Caudill Ph.D.

Chairman

Mr. James P. Panek

Chief Executive Officer; President

Mr. Matthew J. Pfeffer

Chief Financial Officer; Senior Vice President

Mr. Roland Lance Ignon

Vice President

Mr. Piers C. Whitehead

Vice President

Powered By: FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes.
All other data is delayed at least 20 minutes.
By accessing this page, you agree to the following terms and conditions.
Market News provided by MarketMinute.com
Stock Analysis provided by SocialPicks Conference calls info supplied by OpenCompany
Fundamental data supplied by Mergent, Inc.
Stock quote data supplied by Telekurs